BCA
Benchmark Capital Advisors Portfolio holdings
AUM
$101M
Turnover
16.91%
1-Year Est. Return
0.8%
This Fund
S&P 500
This Quarter
Est. Return
+6.65%
1 Year Est. Return
-0.8%
3 Year Est. Return
+29.53%
5 Year Est. Return
+43.22%
10 Year Est. Return
–
AUM
$132M
AUM Growth
+$5.73M
(+4.5%)
Cap. Flow
-$179K
Cap. Flow
% of AUM
-0.14%
Top 10 Holdings %
Top 10 Hldgs %
31.6%
Holding
141
New
11
Increased
30
Reduced
56
Closed
10
Avg Time Held Equity + Options
3
years
Top 10 Avg Time Held Equity + Options
1.8
years
Top 20 Avg Time Held Equity + Options
2.3
years
Avg Time Held Equity only
3
years
Top 10 Avg Time Held Equity only
1.8
years
Top 20 Avg Time Held Equity only
2.3
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Merck
MRK
|
+$1.64M |
| 2 |
Newell Brands
NWL
|
+$1.16M |
| 3 |
Meta Platforms (Facebook)
META
|
+$1.05M |
| 4 |
Apple
AAPL
|
+$1.02M |
| 5 |
Alphabet (Google) Class C
GOOG
|
+$1,000K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$2.2M |
| 2 |
Sarepta Therapeutics
SRPT
|
+$1.44M |
| 3 |
Viasat
VSAT
|
+$1.26M |
| 4 |
iShares Europe ETF
IEV
|
+$1.17M |
| 5 |
Novartis
NVS
|
+$1.07M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 17.42% |
| 2 | Technology | 15.72% |
| 3 | Real Estate | 14.11% |
| 4 | Healthcare | 13.29% |
| 5 | Financials | 11.16% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
26
Alphabet (Google) Class C
GOOG
$4.2T
| $1.59M | 1.2% |
28,500
+18,500
| +185% | +$1,000K |
2017 Q1
5 quarters
|
|
27
Ventas
VTR
$43.2B
| $1.48M | 1.12% |
25,900
+2,700
| +12% | +$141K |
2018 Q1
1 quarter
|
|
28
SRH Total Return Fund
STEW
$1.71B
| $1.47M | 1.11% |
143,400
-3,000
| -2% | -$32.2K |
2016 Q4
6 quarters
|
|
29
DELISTED
Monmouth Real Estate Investment Corp
MNR
| $1.45M | 1.1% |
87,700
-3,000
| -3% | -$46.4K |
2013 Q2
20 quarters
|
|
30
Galectin Therapeutics
GALT
$367M
| $1.41M | 1.07% |
221,700
| – | – |
2013 Q2
20 quarters
|
|
31
Tapestry
TPR
$22.8B
| $1.36M | 1.03% |
29,070
-1,000
| -3% | -$48.1K |
2013 Q2
20 quarters
|
|
32
Delta Air Lines
DAL
$50.4B
| $1.34M | 1.01% |
27,050
+3,700
| +16% | +$197K |
2018 Q1
1 quarter
|
|
33
Netflix
NFLX
$294B
| $1.32M | 1% |
33,770
| – | – |
2016 Q4
6 quarters
|
|
|
SIR
34
DELISTED
SELECT INCOME REIT
SIR
| $1.32M | 1% |
133,201
-10,465
| -7% | -$94.1K |
2014 Q2
16 quarters
|
|
35
Blackstone Senior Floating Rate 2027 Term Fund
BSL
$168M
| $1.24M | 0.94% |
68,628
-700
| -1% | -$12.6K |
2014 Q3
15 quarters
|
|
|
CORR
36
DELISTED
CorEnergy Infrastructure Trust, Inc.
CORR
| $1.2M | 0.91% |
31,868
-1,300
| -4% | -$48.4K |
2017 Q3
3 quarters
|
|
37
Roku
ROKU
$22.7B
| $1.17M | 0.88% |
27,414
+18,100
| +194% | +$660K |
2017 Q4
2 quarters
|
|
38
DELISTED
Volt Information Sciences, Inc.
VOLT
| $1.15M | 0.87% |
338,315
+7,570
| +2% | +$22.9K |
2014 Q3
15 quarters
|
|
|
39
Newell Brands
NWL
$2.33B
| $1.15M | 0.87% |
+44,560
| New | +$1.16M |
2018 Q2
0 quarters
|
|
40
GE Aerospace
GE
$319B
| $1.13M | 0.85% |
17,324
+6,875
| +66% | +$459K |
2013 Q2
20 quarters
|
|
41
CHS Inc 8% Preferred Stock
CHSCP
$316M
| $1.08M | 0.82% |
36,507
-1,800
| -5% | -$53.7K |
2013 Q2
20 quarters
|
|
42
Teva Pharmaceutical Industries Limited
TEVA
$47.5B
| $1.08M | 0.81% |
44,244
-800
| -2% | -$16.3K |
2016 Q1
9 quarters
|
|
|
CEMI
43
DELISTED
Chembio diagnostics, Inc.
CEMI
| $1.07M | 0.81% |
96,235
+21,143
| +28% | +$190K |
2017 Q2
4 quarters
|
|
44
BlackRock Core Bond Trust
BHK
$590M
| $1.05M | 0.79% |
82,294
-760
| -0.9% | -$9.76K |
2014 Q4
14 quarters
|
|
45
DELISTED
DigitalBridge
DBRG
| $1.03M | 0.78% |
41,238
-2,264
| -5% | -$54.1K |
2017 Q1
5 quarters
|
|
46
Goldman Sachs Group Inc Depositary Shares
GS.PRA
$577M
| $1.03M | 0.78% |
43,969
-3,200
| -7% | -$72.1K |
2013 Q2
20 quarters
|
|
47
Medtronic
MDT
$121B
| $1.02M | 0.77% |
11,925
| – | – |
2017 Q4
2 quarters
|
|
48
Avnet
AVT
$7.88B
| $999K | 0.76% |
23,300
-1,500
| -6% | -$60.8K |
2018 Q1
1 quarter
|
|
49
Alibaba
BABA
$277B
| $954K | 0.72% |
5,140
-1,000
| -16% | -$191K |
2017 Q3
3 quarters
|
|
50
Walt Disney
DIS
$188B
| $938K | 0.71% |
8,950
+300
| +3% | +$30.7K |
2013 Q2
20 quarters
|
|
Similar funds
OIMU
7A
JCP
DCM
BCEM
QAM
CFA
BPV
Benchmark Capital Advisors's Q2 2018 Portfolio in Review
As of Q2 2018, Benchmark Capital Advisors held 141 positions worth $132M, up 4.5% from $127M the previous quarter. Its ten largest holdings account for 32% of the portfolio.
Benchmark Capital Advisors's Q2 2018 filing shows 11 new, 30 increased, 56 reduced and 10 closed positions. Its largest new stake was Merck: 29,082 shares worth $1.68M. The largest sale was Bristol-Myers Squibb, an estimated $2.2M.
By sector, the portfolio is most concentrated in Miscellaneous at 17% of assets, down from 20% a quarter earlier, followed by Technology and Real Estate.
- Benchmark Capital Advisors's largest Q2 2018 buy was Merck: 29,082 shares worth $1.68M.
- Benchmark Capital Advisors added most to Meta Platforms (Facebook) in Q2 2018, an estimated $1.05M increase.
- Benchmark Capital Advisors's biggest Q2 2018 reduction was Bristol-Myers Squibb, cutting an estimated $2.2M.
- Benchmark Capital Advisors fully exited Viasat in Q2 2018, selling an estimated $1.26M.
- Benchmark Capital Advisors's ten largest holdings make up 32% of its $132M portfolio in Q2 2018.
- Benchmark Capital Advisors opened 11 new positions and closed 10 in Q2 2018.
- Benchmark Capital Advisors's portfolio value rose 4.5% quarter-over-quarter to $132M.
Based on Benchmark Capital Advisors's 13F filing for Q2 2018, filed 25 Jul 2018.